- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cadila Healthcare to sell 49 pc stake in WHPL to Windlas Biotech for Rs 99.44 cr
![Cadila Healthcare to sell 49 pc stake in WHPL to Windlas Biotech for Rs 99.44 cr Cadila Healthcare to sell 49 pc stake in WHPL to Windlas Biotech for Rs 99.44 cr](https://medicaldialogues.in/h-upload/2020/05/02/750x450_128146-125430-cadila-healthcare.webp)
New Delhi: Drug firm Cadila Healthcare on Thursday said it has signed a definitive pact to sell its 49 per cent stake in Windlas Healthcare to Windlas Biotech for Rs 99.44 crore.
The company's board has approved and signed the agreement for the sale of 2,31,33,717 equity shares of Rs 10 each fully paid-up capital, representing 49 per cent of the total paid-up share capital of Windlas Healthcare Pvt Ltd (WHPL), to Windlas Biotech Pvt Ltd, Cadila Healthcare said in a filing to the BSE.
"Consequent to above divestment and upon completion of the transaction in relation to the sale of the said equity shares, the company shall cease to hold any equity shares in WHPL, it added.
A total of Rs 99,44,07,423 will be received as consideration for the sale, which is expected to be completed within 10 business days, Cadila Healthcare said.
Shares of Cadila Healthcare were trading at Rs 325.95 per scrip on the BSE, down 0.18 per cent from its previous close.
Read also: Treating Coronavirus: Zydus Explores The Biologicals Route With Long-Acting Interferon Alpha-2b
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751